Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
38 hedge funds and large institutions have $57M invested in Adamas Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.3M |
| 2 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
+$9.81M |
| 3 |
WSA
Wall Street Associates
Lajolla,
California
|
+$4.03M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$2.72M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$1.91M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCIM
26
TIAA CREF Investment Management
New York
| $152K | +$149K | +8,335 | New |
|
|
BIM
27
BlackRock Investment Management
Wilmington,
Delaware
| $142K | +$139K | +7,781 | New |
|
28
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| $97K | +$95K | +5,300 | New |
|
|
TA
29
Teachers Advisors
New York
| $76K | +$74.1K | +4,134 | New |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $54K | +$53.2K | +2,969 | New |
|
|
NFA
31
Nationwide Fund Advisors
Columbus,
Ohio
| $38K | +$37K | +2,064 | New |
|
|
AIG
32
American International Group
New York
| $34.9K | +$34.2K | +1,911 | New |
|
33
AllianceBernstein
Nashville,
Tennessee
| $15K | +$14.3K | +800 | New |
|
|
U
34
UBS
Zurich,
Switzerland
| $12K | +$11.4K | +634 | New |
|
|
VFA
35
Virtus Fund Advisers
Hartford,
Connecticut
| $5K | +$4.46K | +249 | New |
|
36
Wells Fargo
San Francisco,
California
| $4K | +$3.73K | +208 | New |
|
37
Barclays
London,
United Kingdom
| $1K | +$1.15K | +64 | New |
|
38
Citigroup
New York
| $1K | +$1.15K | +64 | New |
|
ADMS Hedge Fund Activity: Q2 2014 in Review
38 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q2 2014, worth a combined $57M.
Buyers outnumbered sellers: 38 funds opened new ADMS positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $23.3M.
- 38 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q2 2014, up from 0 in Q1 2014.
- Funds reported $57M of Adamas Pharmaceuticals stock for Q2 2014.
- 38 funds opened new Adamas Pharmaceuticals positions in Q2 2014 and 0 closed out, a net change of +38 holders.
- The largest Adamas Pharmaceuticals buyer in Q2 2014 was Fidelity Investments, an estimated $23.3M added.
Based on aggregated 13F filings for Q2 2014.